ARC-1779, a PEGylated aptamer antagonist of von willebrand factor for potential use as an anticoagulant or antithrombotic agent

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 3, 2009, Pages 322-328

  Cosmi, Benilde ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APTAMER; ARC 1779; CLOPIDOGREL; DESMOPRESSIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; RITUXIMAB; THIENOPYRIDINE DERIVATIVE; TIROFIBAN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AREA UNDER THE CURVE; ARTERY THROMBOSIS; BLEEDING; BOLUS INJECTION; BRAIN EMBOLISM; CEREBRAL MICROEMBOLISM; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; LOADING DRUG DOSE; MEAN RESIDENCE TIME; NONHUMAN; OPTIMAL DRUG DOSE; PROTEIN CONFORMATION; PROTEIN TARGETING; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VON WILLEBRAND DISEASE;

ANIMALS; ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; HUMANS; PATENTS AS TOPIC; POLYETHYLENE GLYCOLS; STRUCTURE-ACTIVITY RELATIONSHIP; VON WILLEBRAND FACTOR;

EID: 67650236718     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. 633391 Pre-clinical evaluation of an anti-von Willebrand factor aptamer for treatment of acute coronary syndrome. Rottman JB, Lagasse HAD, Benedict C, McCauley T, Hutabarat R, Merlino P, Makim A, Lewis S, Marsh NH, Cunningham MR, Nedelman M CIRCULATION 2005 112 17 Suppl Abs 1222
2. 811310 An anti-von Willebrand's factor A1 domain aptamer inhibits arterial thrombosis induced by electrical injury in cynomolgus macaques. Rottman JB, Gilbert M, Marsh HN, Boomer RM, Fraone JM, Makim A, Lewis SD, Cai L, McCauley T, Hutabarat R, Diener R CONGRESS INT SOC THROMB HAEMOSTATSIS 2007 XXIst July 8 Abs P-S-664
3. 811349 Inhibition of platelet function by the anti-von Willebrand factor aptamer, ARC1779. Merlino PG, Gilbert M, Lagasse H, Diener JL, Marsh H CONGRESS INT SOC THROMB HAEMOSTATSIS 2007 XXIst July 9 Abs P-M-346
4. 849788 The aptamer ARC1779 is a potent and specifc inhibitor of von Willebrand factor (vWF) mediated ex vivo platelet function in ST-elevation (STEMI) and non-ST elevation (NSTEMI) acute myocardial infarction (AMI). Jilma B, Mayr FB, Spiel AO, Merlino PG, Marsh HN, Schaub R, Gilbert R AM HEART ASSOC SCIENTIFIC SESSIONS 2007 November 05 Abs 2214
5. 850768 Pharmacokinetics, pharmacodynamics and safety of an anti-von Willebrand factor therapeutic aptamer, ARC1779, in healthy volunteers. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Fahkreddine SB, Holohan TV, Schaub R AM HEART ASSOC SCIENTIFIC SESSIONS 2007 November 07 Abs 3218
6. 850867 Archemix announces initiation of phase 2a trial for aptamer product candidate ARC1779 in patients with acute coronary syndrome. Archemix Corp PRESS RELEASE 2007 November 13
7. 856259 The aptamer ARC1779 potently and specifcally inhibits the excessive von Willebrand factor (vWF) activity and vWF-mediated ex vivo platelet function of patients with thrombotic thrombocytopenic purpura (TTP). Jilma B, Mayr FM, Knoebl P, Spiel AO, Merlino PG, Schaub R, Gilbert J AM SOC HEMATOL ANN MEET EXPOSITION 2007 49th December 10 Abs 279
8. 886804 Archemix and Nuvelo begin phase II trial of ARC-1779 for thrombocytopenia. Archemix Corp PRESS RELEASE 2008 March 17
9. 896997 First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG CIRCULATION 2007 116 23 2678-2686
10. 897000 Pre-clinical evaluation of an anti-von Willebrand Factor aptamer for treatment of acute coronary syndrome. Rottman JB, Lagasse HAD, Benedict C, McCauley T, Hutabarat R, Merlino P, Makim A, Lewis S, Marsh HN, Cunningham MR, Nedelman M et al CIRCULATION 2005 112 17 U295
11. 897002 Discovery and pre-clinical evaluation of an anti-vWF aptamer for treatment of acute coronary syndrome (ACS). Archemix Corp ARTERIOSCLER THROMB VASC BIOL 2005 25 5 P79
12. 898864 Archemix' ARC1779 ganted orphan designation for the treatment of TTP, a life-treatening blood disorder. Archemix Corp PRESS RELEASE 2008 April 22
13. 923178 Archemix' ARC1779 granted orphan designation in EU for the treatment of TTP, a life-threatening blood disorder. Archemix Corp PRESS RELEASE 2008 July 07
14. 957676 The anti von Willebrand factor aptamer ARC1779 effectively inhibits platelet activation and adhesion. Duerschmied D, Wagner P, Gilbert M, Gilbert J, Wagner D, Schaub R AM HEART ASSOC SCIENTIFIC SESSIONS 2008 November 10 Abs 1941
15. 967648 Proof of concept for the anti von Willebrand factor aptamer in patients with relapsing thrombotic thrombocytopenic purpura (TTP). Jilma B, Jilma P, Paulinska P, Gilbert JC, Hutabarat R, Wagner T, Knoebl P AM SOC HEMATOL ANN MEET EXPOSITION 2008 50th December 7 Abs 2290
16. 967689 Anti von Willebrand factor aptamer ARC 1779 for refractory thrombotic thrombocytopenic purpura. Firbas C, Jilma B, Wagner PG, Hutabarat R, Schaub RG, Gilbert JC, Knoebl P AM SOC HEMATOL ANN MEET EXPOSITION 2008 50th December 7 Abs 2298
17. 967956 The anti von Willebrand factor aptamer ARC1779 prevents the desmopressin-induced thrombocytopenia in VWD type 2b. Paulinska P, Jilma B, Firbas C, Schaub RG, Gilbert JC, Knoebl P AM SOC HEMATOL ANN MEET EXPOSITION 2008 50th December 08 Abs 3374
18. 979526 Archemix announces continued progress with business strategy. Archemix Corp PRESS RELEASE 2009 January 27
19. 979562 NCT00694785: A study of the pharmacokinetics, pharmacodynamics, and safety of ARC1779 injection in patients with von Willebrand disease type 2B, CLINICALTRIALS.GOV 2008
20. 984475 Anti-coagulant aptamers. Gopinath SCB THROMB RES 2008 122 6 838-847
21. 984477 Aptamers as candidate therapeutics for cardiovascular indications. Keefe AD, Schaub RG CURR OPIN PHARMACOL 2008 8 2 147-152
22. 984479 vWF attributes - impact on thrombus formation. Reininger AJ THROMB RES 2008 122 Suppl 4 S9-S13
23. 984480 The role of von Willebrand factor in thrombus formation. Ruggeri ZM THROMB RES 2007 120 Suppl 1 S5-S9
24. 984481 Platelet adhesion: A game of catch and release. Andrews RK, Berndt MC J CLIN INVEST 2008 118 9 3009-3011
25. 984482 von Willebrand factor, ADAMTS13 and thrombotic thrombocytopenic purpura. Sadler EJ Blood 2008 112 1 11-12
26. 984483 New antithrombotic drugs: American College of Chest Physicians evidence-based Clinical Practice Guidelines (8th edition). Weitz JI, Hirsh J, Samama MM CHEST 2008 133 6 Suppl 234S-256S
27. 986850 P2Y12 antagonism: Promises and challenges. Michelson AD ARTERIOSCLER THROMB VASC BIOL 2008 28 3 s33-s38
28. 988623 Use of antiplatelet agents and anticoagulants for cardiovascular disease: Current standards and best practices. Faxon DP REV CARDIOVASC MED 2005 6 Suppl 4 3-14
29. 988628 Antiplatelet agents and arterial thrombosis. Billett HH CARDIOL CaLIN 2008 26 2 189-201
30. 988633 Anticoagulants in coronary artery disease. Lee LV CARDIOL CLIN 2008 26 4 615-628
31. 988713 Management of inherited von Willebrand disease in 2007. Federici AB, Mannucci PM ANN MED 2007 39 5 346-358
32. 995177 Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ PHARMACOL EXP THER 1997 281 2 810-816.
33. 1000408 Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies. García Rodríguez LA, Hernandez-Díaz S, de Abajo FJ BR J CLIN PHARMACOL 2001 52 563-571